COMMUNIQUÉS West-GlobeNewswire

EDAP TMS SA : John Wayne Cancer Institute First US Medical Center to Acquire EDAP's Breakthrough Focal One® Technology for Prostate Tissue Ablation
03/01/2019
Focal One System Enhances Precision Tissue Ablation, Reduces Side Effects for Prostate Cancer Patients LYON, France -- January 3, 2019 - EDAP TMS SA (Nasdaq: EDAP) today announced that the John Wayne Cancer Institute ( [...]
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
03/01/2019
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth [...]
Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
03/01/2019
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
03/01/2019
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two new medical [...]
Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer
03/01/2019
Phase 1 Data Expected the First Half of 2019 SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for SM08502 [...]
Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
03/01/2019
RP1: U.S. Enrollment Opened for Phase 1/2 Clinical Trial in Combination with Nivolumab in Patients with Solid Tumors RP1: Randomized Controlled Phase 2 Clinical Trial Alone and in Combination with Cemiplimab On Track to [...]
Fulgent Genetics and Columbia University Irving Medical Center Partner on Expanded Carrier Screening
03/01/2019
TEMPLE CITY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) and the Precision Genomics Laboratory (PGL), in collaboration with the Department of Obstetrics and Gynecology, at Columbia [...]
Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference
03/01/2019
BERKELEY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 37 [...]
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program
03/01/2019
Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program FDA pilot program is a 21 st Century Cures Act initiative CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. ( [...]
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
03/01/2019
Dose Escalation Trial in Patients with Solid Tumors CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of [...]
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cell-Mediated Autoimmune Diseases
03/01/2019
Deerfield Management Company, Boxer Capital of Tavistock Group, Redmile Group and Cormorant Capital join founding investors Adage Capital, an undisclosed leading public equity healthcare investor and 5AM Ventures RADNOR [...]
AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
03/01/2019
Lausanne, Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today announced that it has [...]
MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
03/01/2019
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys B ioscience, Inc ., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has submitted a pre-IND ( [...]
Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554
03/01/2019
Tara Rheault, PhD, MPH, named Vice President, R&D Operations and Global Project Management LONDON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage [...]
GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic SteatoHepatitis (NASH)
03/01/2019
GENFIT AND LABCORP SIGN A LICENSING AGREEMENT TO EXPAND ACCESS TO AN INNOVATIVE DIAGNOSTIC ASSAY FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) Multi-Biomarker Test Will Provide the Clinical Research Community with a Non- [...]
GENFIT et LabCorp signent un accord de licence visant l'élargissement de l'accès à un test diagnostique innovant de la stéatohépatite non-alcoolique (NASH)
03/01/2019
GENFIT ET LABCORP SIGNENT UN ACCORD DE LICENCE VISANT L'ÉLARGISSEMENT DE L'ACCÈS À UN TEST DIAGNOSTIQUE INNOVANT DE LA STÉATOHÉPATITE NON-ALCOOLIQUE (NASH) Ce test, basé sur plusieurs biomarqueurs, fournira à la [...]
DBV Technologies Expands and Strengthens Leadership Team
03/01/2019
Montrouge, France, January 3, 2019 DBV Technologies Expands and Strengthens Leadership Team Key medical, manufacturing and regulatory leadership changes announced ahead of anticipated Viaskin Peanut BLA resubmission Dr [...]
DBV Technologies étend et renforce son équipe de management
03/01/2019
Montrouge, France, le 3 janvier (07h30 CET), 2019 DBV Technologies étend et renforce son équipe de management Des changements importants au niveau des directions médicales, des opérations pharmaceutiques, et du [...]
Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™
03/01/2019
Accelerates European Development of PSMA-Targeted Imaging Agent with Global Leader in Nuclear Medicine NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company [...]

Pages